Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Frenova LLC

Neither a doctor nor a teaching hospital

Research payments

$9,830,644

13,749 payments

Through program year 2025, Frenova LLC is reported as receiving $9,830,644 in research payments, across 13,749 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $19,737 8
2024 Research $186,738 48
2023 Research $413,370 80
2022 Research $329,843 46
2021 Research $2,406,514 9,318
2020 Research $2,497,592 373
2019 Research $3,976,850 3,876

Breakdown

Who paid Research payments · program years 2019–2025
  1. Akebia Therapeutics Inc $8,273,039 13,491 payments
  2. Pfizer Inc. $668,295 91 payments
  3. Horizon Therapeutics plc $243,261 11 payments
  4. Otsuka Pharmaceutical Co., Ltd. $203,194 46 payments
  5. Medtronic Vascular, Inc. $132,859 5 payments
  6. Eli Lilly and Company $96,665 10 payments
  7. Retrophin, Inc. $68,858 61 payments
  8. AstraZeneca Pharmaceuticals LP $50,642 20 payments
  9. Medtronic, Inc. $35,855 6 payments
  10. Novartis Pharmaceuticals Corporation $27,464 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Akb-6548-Ci-0017 $2,880,176 2,916 payments
  2. Akb-6548-Ci-0017 $1,798,214 8,796 payments
  3. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (Dd-Ckd) (Inno2vate-Conversion) $1,276,914 198 payments
  4. A Phase 1 Openlabel Nonrandomized Study to Investigate the Safety and PK Following Multiple Oral Doses of Pf07321332 Nirmatrelvirritonavir in Adult Participants With Covid19 and Severe Renal Impairment Either on Hemodialysis Or Not on Hemodialysis $668,295 91 payments
  5. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $550,928 72 payments
  6. Akb-6548-Ci-0016 $470,048 438 payments
  7. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction Or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-Dependent Chronic Kidney Disease (Dd-Ckd) (Inno2vate - Correction/Conversion) $400,050 73 payments
  8. Akb-6548-Ci-0014 $359,538 349 payments
  9. IN.PACT AV Access $168,714 11 payments
  10. Akb-6548-Ci-0015 $160,755 150 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $33,767 34 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record